Cargando…

Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA

Tirabrutinib is an irreversible, small‐molecule Bruton’s tyrosine kinase (BTK) inhibitor, which was approved in Japan (VELEXBRU) to treat B‐cell malignancies and is in clinical development for inflammatory diseases. As an application of model‐informed drug development, a semimechanistic pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Amy, Humeniuk, Rita, Jürgensmeier, Juliane M., Hsueh, Chia‐Hsiang, Matzkies, Franziska, Grant, Ethan, Truong, Hoa, Billin, Andrew N., Yu, Helen, Feng, Joy, Kwan, Ellen, Tarnowski, Thomas, Nelson, Cara H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298258/ https://www.ncbi.nlm.nih.gov/pubmed/34623640 http://dx.doi.org/10.1002/cpt.2439

Ejemplares similares

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
por: Yu, Helen, et al.
Publicado: (2018)

BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib
por: Jackson, Ross A., et al.
Publicado: (2023)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2020)

Evaluation of the potential for pharmacokinetic interaction between tirabrutinib and levonorgestrel/ethinyl estradiol in healthy female volunteers
por: Cherala, Ganesh, et al.
Publicado: (2022)

A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy
por: Daryaee, Fereidoon, et al.
Publicado: (2017)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
por: Kozaki, Ryohei, et al.
Publicado: (2018)

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function
por: Tullemans, Bibian M.E., et al.
Publicado: (2021)

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study
por: Price, Elizabeth, et al.
Publicado: (2022)

Bing-Neel Syndrome Successfully Treated with Tirabrutinib
por: Oyama, Takashi, et al.
Publicado: (2022)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2022)

Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase
por: Li, Ping, et al.
Publicado: (2020)

Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib
por: Yasuda, Hajime, et al.
Publicado: (2022)

The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenström's Macroglobulinemia
por: Sekiguchi, Naohiro
Publicado: (2022)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

P1247: GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES
por: Yusuf, I., et al.
Publicado: (2022)

Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma
por: Ding, Ning, et al.
Publicado: (2015)

Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
por: Okita, Yoshiko, et al.
Publicado: (2021)

Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib
por: Sekiguchi, Yasunobu, et al.
Publicado: (2022)

Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib
por: Iizuka-Honma, Hiroko, et al.
Publicado: (2022)

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
por: Grant, Joshuaine, et al.
Publicado: (2023)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib
por: Sasaki, Nobuyoshi, et al.
Publicado: (2021)

Successful treatment with tirabrutinib for relapsed Bing-Neel syndrome following high-dose methotrexate and craniospinal irradiation
por: Saburi, Masuho, et al.
Publicado: (2022)

Dose Optimization of Aditoprim-Sulfamethoxazole Combinations Against Trueperella pyogenes From Patients With Clinical Endometritis by Using Semi-mechanistic PK/PD Model
por: Maan, Muhammad Kashif, et al.
Publicado: (2021)

A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2020)

Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia
por: Nakagawa, Noriharu, et al.
Publicado: (2022)

Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics
por: Kozaki, Ryohei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9vsc91h06bs4mcff86h6df889i